Willow Biosciences Inc.

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
0.085 ^CAD	-5.56%		-10.53%	-15.00%

May. 13	Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	MT
May. 13	Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Willow Bioscience agrees to partnership with biotech company looking at age-related diseases

June 02, 2023 at 11:52 am EDT

(via NewsDirect)

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has agreed to a Master Services Agreement with an innovative biotech company with the focus on age-related diseases. This partnership will see the company develop precision fermentation processes for a class of molecules to develop novel solutions for age-related diseases.

Savile also told Proactive about another key partnership with Kalsec Inc to develop an enzyme used in production of a new, advanced ingredient used in natural beverage applications. This is the second collaborative development program the two parties will be working on. The goal is to commercialize these products quickly and effectively, leveraging partnerships for market access while retaining the option to bring proprietary ingredients to market independently.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

Latest news about Willow Biosciences Inc.

Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	May. 13	MT
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Willow Biosciences Narrows 2023 Loss YOY	Apr. 01	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	Mar. 01	MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient	Feb. 21	MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.	Feb. 19	CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	Jan. 31	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	Jan. 31	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	Jan. 31	CI
Willow Biosciences Announces Collaboration With Enterin	Jan. 16	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	Jan. 16	CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights	Jan. 10	MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024	Jan. 10	MT
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue	Dec. 07	DJ
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program	Dec. 07	MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program	Dec. 07	MT
Willow Biosciences Reports Q3 Results, Provides Update	Nov. 15	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Willow Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Aurora Cannabis Announcing Settlement of Patent Litigation	23-10-24	MT
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding	23-10-09	CI
Willow Biosciences and Suanfarma Detail Collaboration	23-10-03	MT
Willow Biosciences Inc. and Suanfarma Announce Collaboration on Development of Large Volume Anti-Infective API Through Precision Fermentation	23-10-03	CI
Willow Biosciences Announced Company Insider Led Convertible Debenture Financing	23-09-12	MT

Chart Willow Biosciences Inc.

Duration

Period

More charts

Company Profile

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
WILLOW BIOSCIENCES INC.	-15.00%	7.91M
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.73%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.28%	14.52B
INCYTE CORPORATION	-8.50%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B